Study: CSII treatment boosts glucose control in type 1 diabetes

Continuous subcutaneous insulin infusion treatment was effective in lowering A1C levels in children with type 1 diabetes, with improvements sustained at 48 months, according to a study presented at the annual meeting of the Pediatric Academic Societies. CSII treatment lacks cost-effectiveness but is safe and well-tolerated compared with multiple daily injections, researchers said.

View Full Article in:

CSII therapy improved HbA1c in children with type 1 diabetes - Endocrine Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA